<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980395</url>
  </required_header>
  <id_info>
    <org_study_id>0800001071</org_study_id>
    <secondary_id>P30CA023074</secondary_id>
    <secondary_id>UARIZ-08-1071-04</secondary_id>
    <secondary_id>X05260</secondary_id>
    <secondary_id>CDR0000655078</secondary_id>
    <secondary_id>0800001071</secondary_id>
    <secondary_id>08-1071-04</secondary_id>
    <nct_id>NCT00980395</nct_id>
  </id_info>
  <brief_title>Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma</brief_title>
  <acronym>VCR</acronym>
  <official_title>A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
      needed for cell growth. Drugs used in chemotherapy, such as cladribine, work in different
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from
      dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
      help kill them or carry cancer-killing substances to them. Giving bortezomib together with
      cladribine and rituximab may kill more cancer cells.

      PURPOSE: This phase II trial is studying how well giving bortezomib together with cladribine
      and rituximab works in treating patients with advanced mantle cell lymphoma or indolent
      lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the 2-year progression-free survival of patients with advanced mantle cell
           lymphoma or indolent lymphoma treated with bortezomib, cladribine, and rituximab.

      Secondary

        -  Determine the 2-year overall survival of patients treated with this regimen.

        -  Determine the complete response and overall response rate in patients treated with this
           regimen.

        -  Describe the long- and short-term toxicity of this regimen in these patients.

        -  Determine the prognostic importance of Aurora kinase A in patients treated with this
           regimen.

        -  Determine the cytokine profiles for each lymphoma subtype and how they change with this
           regimen.

        -  Evaluate the prognostic importance of major carcinogenic pathways using tissue
           microarray.

      OUTLINE: Patients receive bortezomib IV on days 1 and 4, cladribine IV over 2 hours on days
      1-5, and rituximab IV on day 1. Treatment repeats every 28 days for up to 6 courses in the
      absence of disease progression or unacceptable toxicity.

      Blood samples are collected at baseline and after course 1 for cytokine profile studies.
      Previously collected tissue samples are obtained for analysis of Aurora kinase A and B,
      Ki-67, cyclin D, Bcl-2, phosphor-HisH3, c-Met, and VEGF expression by using tissue microarray
      (IHC staining), reverse transcriptase-PCR, and/or western blotting.

      After completion of study therapy, patients are followed up every 3 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2009</start_date>
  <completion_date type="Actual">August 14, 2018</completion_date>
  <primary_completion_date type="Actual">September 12, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival at 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>PFS was calculated from the first dose of study drug to the first documentation of disease progression, death regardless of cause, or change in therapy due to disease progression, whichever occurred first. If disease progression did not occur by the end of treatment, patients were evaluated every 3 months until progression with physical examination, laboratory studies, and conventional computed tomographic imaging, up to a maximum of 2 years. The Kaplan-Meier product-limit method will be used to estimate progression-free survival in the presence of censoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 2 Years</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Indolent Lymphoma</condition>
  <condition>SLL</condition>
  <arm_group>
    <arm_group_label>VCR (Velcade, Cladribine and Rituximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab 375 mg/m2 IV day1
Cladribine 4 mg/m2 IV over 2 hours days 1-5
Bortezomib 1.3 mg/m2 IV days 1 and 4
Repeat every 28 days for a maximum of 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.</description>
    <arm_group_label>VCR (Velcade, Cladribine and Rituximab)</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.</description>
    <arm_group_label>VCR (Velcade, Cladribine and Rituximab)</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cladribine</intervention_name>
    <description>4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.</description>
    <arm_group_label>VCR (Velcade, Cladribine and Rituximab)</arm_group_label>
    <other_name>Leustatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary consent before performance of any study-related procedure

          -  Female subject is either post-menopausal or surgically sterilized or willing to use an
             acceptable method of birth control

          -  Male subject agrees to use an acceptable method for contraception for the duration of
             the study.

          -  Biopsy-proven mantle cell, marginal zone, lymphoplasmacytic, small lymphocytic
             lymphoma, or follicular lymphoma

          -  CD20-positive disease

          -  Patients with marginal zone, lymphoplasmacytic, small lymphocytic, or follicular
             lymphoma - at least one criterion for initiation of treatment must be met:

               -  Symptomatic disease

               -  Cytopenia related to lymphoma

               -  Leukemic phase (&gt; 5,000 malignant lymphocytes/µl)

               -  Mass over 5 cm in greatest diameter

               -  For lymphoplasmacytic lymphoma: additional treatment criteria are serum viscosity
                  ≥ 4 cp, serum monoclonal protein &gt; 5 g/L, concurrent primary systemic AL
                  amyloidosis, cold agglutinin disease

          -  Age over 18

          -  Prior treatment with bortezomib and/or rituximab is acceptable

          -  For follicular lymphoma only, at least one prior treatment

        Exclusion Criteria:

          -  Platelet count of &lt; 100 X10 /L within 14 days before enrollment, unless due to bone
             marrow infiltration with lymphoma, or due to autoimmune thrombocytopenia because of
             lymphoma.

          -  Patient has an absolute neutrophil count of &lt; 1.0 X 10/L within 14 days before
             registration, unless due to bone marrow infiltration with lymphoma.

          -  Patient has a calculated or measured creatinine clearance of &lt;20 mL/minute within 14
             days before registration. (Creatinine Clearance is indicated through the Serum
             Creatinine. If the Serum Creatinine is abnormal, the physician may then due a 24 hour
             urine to further clarify Creatinine Clearance. A 24 hour urine test is not required
             per study.)

          -  Patient has ≥ Grade 2 peripheral neuropathy within 14 days before registration.

          -  Myocardial infarction within 6 months prior to registration or has New York Heart
             Association (NYHA) Class III or IV heart failure. uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities.

          -  Hypersensitivity to bortezomib, boron or mannitol.

          -  Female subject is pregnant or breast-feeding. Confirmation that the subject is not
             pregnant

          -  Patient received other investigational drugs with 14 days before registration

          -  Serious medical or psychiatric illness likely to interfere with study participation

          -  Diagnosed or treated for another malignancy within 3 years of registration, w/ the
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.

          -  CNS involvement with lymphoma.

          -  Known HIV-positive.

          -  History of disease refractory to a purine analog (defined as remission duration of &lt; 6
             months to therapy that included fludarabine, pentostatin, or cladribine).

          -  History of intolerance of bortezomib, boron, mannitol, cladribine, or rituximab.

          -  Patient has &gt; 1.5 X ULN Total Bilirubin

          -  Radiation therapy within 3 weeks before randomization. Enrollment of subjects who
             require concurrent radiotherapy (which must be localized in its field size) should be
             deferred until the radiotherapy is completed and 3 weeks have elapsed since the last
             date of therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel O. Persky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <results_first_submitted>September 24, 2019</results_first_submitted>
  <results_first_submitted_qc>October 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2019</results_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>extranodal marginal zone BCL mucosa assoc lymphoid tissue</keyword>
  <keyword>nodal marginal zone B Cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT00980395/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VCR (Velcade, Cladribine and Rituximab)</title>
          <description>Rituximab 375 mg/m2 IV day1
Cladribine 4 mg/m2 IV over 2 hours days 1-5
Bortezomib 1.3 mg/m2 IV days 1 and 4
Repeat every 28 days for a maximum of 6 cycles
rituximab: 375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
bortezomib: 1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
cladribine: 4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VCR (Velcade, Cladribine and Rituximab)</title>
          <description>Rituximab 375 mg/m2 IV day1
Cladribine 4 mg/m2 IV over 2 hours days 1-5
Bortezomib 1.3 mg/m2 IV days 1 and 4
Repeat every 28 days for a maximum of 6 cycles
rituximab: 375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
bortezomib: 1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
cladribine: 4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.5" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Mantle-cell lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Follicular lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Marginal zone lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lymphoplasmacytic lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Small lymphocytic lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival at 2 Years</title>
        <description>PFS was calculated from the first dose of study drug to the first documentation of disease progression, death regardless of cause, or change in therapy due to disease progression, whichever occurred first. If disease progression did not occur by the end of treatment, patients were evaluated every 3 months until progression with physical examination, laboratory studies, and conventional computed tomographic imaging, up to a maximum of 2 years. The Kaplan-Meier product-limit method will be used to estimate progression-free survival in the presence of censoring.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VCR (Velcade, Cladribine and Rituximab)</title>
            <description>Rituximab 375 mg/m2 IV day1
Cladribine 4 mg/m2 IV over 2 hours days 1-5
Bortezomib 1.3 mg/m2 IV days 1 and 4
Repeat every 28 days for a maximum of 6 cycles
rituximab: 375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
bortezomib: 1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
cladribine: 4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival at 2 Years</title>
          <description>PFS was calculated from the first dose of study drug to the first documentation of disease progression, death regardless of cause, or change in therapy due to disease progression, whichever occurred first. If disease progression did not occur by the end of treatment, patients were evaluated every 3 months until progression with physical examination, laboratory studies, and conventional computed tomographic imaging, up to a maximum of 2 years. The Kaplan-Meier product-limit method will be used to estimate progression-free survival in the presence of censoring.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival at 2 Years</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VCR (Velcade, Cladribine and Rituximab)</title>
            <description>Rituximab 375 mg/m2 IV day1
Cladribine 4 mg/m2 IV over 2 hours days 1-5
Bortezomib 1.3 mg/m2 IV days 1 and 4
Repeat every 28 days for a maximum of 6 cycles
rituximab: 375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
bortezomib: 1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
cladribine: 4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at 2 Years</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response Rate</title>
        <time_frame>Two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VCR (Velcade, Cladribine and Rituximab)</title>
            <description>Rituximab 375 mg/m2 IV day1
Cladribine 4 mg/m2 IV over 2 hours days 1-5
Bortezomib 1.3 mg/m2 IV days 1 and 4
Repeat every 28 days for a maximum of 6 cycles
rituximab: 375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
bortezomib: 1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
cladribine: 4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial Response</title>
        <time_frame>Two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VCR (Velcade, Cladribine and Rituximab)</title>
            <description>Rituximab 375 mg/m2 IV day1
Cladribine 4 mg/m2 IV over 2 hours days 1-5
Bortezomib 1.3 mg/m2 IV days 1 and 4
Repeat every 28 days for a maximum of 6 cycles
rituximab: 375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
bortezomib: 1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
cladribine: 4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Response</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>107 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>VCR (Velcade, Cladribine and Rituximab)</title>
          <description>Rituximab 375 mg/m2 IV day1
Cladribine 4 mg/m2 IV over 2 hours days 1-5
Bortezomib 1.3 mg/m2 IV days 1 and 4
Repeat every 28 days for a maximum of 6 cycles
rituximab: 375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
bortezomib: 1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
cladribine: 4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Selegue, NCTN Program Coordinator</name_or_title>
      <organization>University of Arizona</organization>
      <phone>520-626-0301</phone>
      <email>aselegue@email.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

